Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
8:00am - 8:55am

Registration

More
Showing of Streams
10:30am - 11:00am

Networking Refreshment Break

More
Showing of Streams
12:30pm - 1:30pm

Networking Luncheon

More
Showing of Streams
3:00pm - 3:30pm

Networking Refreshment Break

More
Showing of Streams
8:00am - 8:55am 55 mins
Registration
8:55am - 9:00am 5 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Chairperson's Remarks
8:55am - 9:00am 5 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Chairperson's Remarks
8:55am - 9:00am 5 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Chairperson's Remarks
9:00am - 9:30am 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
CMO perspective on vector manufacturing; ensuring supply
9:00am - 9:30am 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Development if Tissue Therapies as compared to the Development of Cell and Gene Therapies: A Look Back, A Look Ahead
9:00am - 9:30am 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Novel T Cell Approaches
9:30am - 10:00am 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Small biotech considerations – Risk mitigation in ensuring supply of vectors
9:30am - 10:00am 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Raw Materials/Starting Materials
9:30am - 10:00am 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Off-the shelf, TCR-transduced T cells for solid cancers
  • Ali Mohamed - VP, CMC, Immatics, USA
10:00am - 10:30am 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Alternatives to viral vectors for gene therapies
10:00am - 10:30am 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Cell Culture and Expansion
10:00am - 10:30am 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Gamma Delta T cells for the treatment of Cancer
  • Michael Leek - Chief Executive, TC BioPharm
10:30am - 11:00am 30 mins
Networking Refreshment Break
11:00am - 12:00pm 60 mins
Info
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Dual Dialogue: Media supply chain- matching incoming materials to required throughput

Looking for 2 speakers to discuss risk mitigation/scaling up considerations for 2 types of product 

11:00am - 11:30am 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Cell Harvest
11:00am - 11:30am 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
CAR Macrophage Immunotherapy to target Solid Tumors
  • Michael Klichinsky - Co-Founder, Carisma Therapeutics
11:30am - 12:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Scaffold Fabrication – 3D Printing
11:30am - 12:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
CAR T Combination Therapies
12:00pm - 12:30pm 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Finding a golden standard in chemically defined media; moving away from animal products
12:00pm - 12:30pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Scaffold Fabrication
12:00pm - 12:30pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Bispecific CAR-T Cells for Solid Tumor Targeting
12:30pm - 1:30pm 60 mins
Networking Luncheon
1:30pm - 2:30pm 60 mins
Info
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Auto vs. Allo Supply chain considerations; incorporating starting materials into your process
  • Joseph Carosi - Associate Director, Novartis, USA

Looking for one auto and one allo manufacturer to discuss how they are incorporating raw materials into their current process/chain of custody etc. 

1:30pm - 2:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Tissue Maturation and Bioreactor Culture
1:30pm - 2:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Novel Strategies to Activate, Target and Gene Modify NK Cells for Off-The-Shelf Cancer Therapy
  • Jeffrey Miller - Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota, Roger L. and Lynn C. Headrick Family Chair in Cancer Therapeutics, USA
2:00pm - 2:30pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Tissue Maturation and Bioreactor Culture
2:00pm - 2:30pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Signal 3 Modified T Cells
  • Bilal Omer - Assistant Professor, Baylor College of Medicine, USA
2:30pm - 3:00pm 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Alternatives to traditional starting materials: Cord Blood
2:30pm - 3:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Preservation and Transport
2:30pm - 3:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
CAR-T 2.0 Cell Design Labs (Gilead Case Study) – Synthetic Gene Circuits
3:00pm - 3:30pm 30 mins
Networking Refreshment Break
3:30pm - 4:00pm 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Regulatory considerations concerning continuous supply of raw materials
  • Jakub Cierny - Senior Quality Compliance Manager, Sotio AS, Czech Republic
3:30pm - 4:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Quality Systems
3:30pm - 4:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
An Innovative Proprietary Off-the-Shelf T-Cell Immunotherapy Technology Platform
4:00pm - 4:30pm 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Transportation of materials to manufacturing site: Infrastructure Considerations
4:00pm - 4:30pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Process Development Through multiomic platform
4:00pm - 4:30pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Feedback on the first FDA approved Allogeneic CAR-T Cell Therapy Trial
4:30pm - 5:00pm 30 mins
Info
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Discussion panel: Supplier qualification and considerations
  • Jakub Cierny - Senior Quality Compliance Manager, Sotio AS, Czech Republic
  • Joseph Carosi - Associate Director, Novartis, USA

Looking for 3-5 panelists to discuss supplier qualification, auditing, and different resource for finding raw/starting materials suppliers 

4:30pm - 5:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Data Management and Process Optimization Software
4:30pm - 5:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
End of session wrap up and Q&A